Century Therapeutics (IPSC) Non-Current Deffered Revenue (2022 - 2024)
Century Therapeutics (IPSC) posted quarterly Non-Current Deffered Revenue of $109.8 million for Q3 2024, down 2.12% year-over-year from $112.2 million in Q4 2023, and little changed quarter-over-quarter from $109.8 million in Q2 2024.
Century Therapeutics (IPSC) Non-Current Deffered Revenue (2022 - 2024) Analysis & Trends
Century Therapeutics (IPSC) has reported Non-Current Deffered Revenue for 3 consecutive years, with $109.8 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Non-Current Deffered Revenue fell 2.12% year-over-year to $109.8 million; the TTM figure through Sep 2024 stood at $109.8 million (down 2.12% YoY), while the FY2023 annual figure was $111.4 million, changed 0.49% from the prior year.
- Non-Current Deffered Revenue was little changed at $109.8 million in Q3 2024 per IPSC's latest filing, from $109.8 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $115.8 million in Q1 2022 and bottomed at $109.2 million in Q2 2023.
- Historically, Non-Current Deffered Revenue has averaged $111.2 million across 3 years, with a median of $110.8 million in 2022.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 1.09% in 2023 and fell as far as 5.17% in 2023.
- Century Therapeutics' Non-Current Deffered Revenue stood at $110.8 million in 2022, then rose by 0.49% to $111.4 million in 2023, then dropped by 1.45% to $109.8 million in 2024.
- Business Quant data shows IPSC's Non-Current Deffered Revenue at $109.8 million in Q3 2024, $109.8 million in Q2 2024, and $110.3 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 109.77 Mn |
| Jun 30, 2024 | 109.77 Mn |
| Mar 31, 2024 | 110.29 Mn |
| Dec 31, 2023 | 111.38 Mn |
| Sep 30, 2023 | 112.15 Mn |
| Jun 30, 2023 | 109.23 Mn |
| Mar 31, 2023 | 109.77 Mn |
| Dec 31, 2022 | 110.83 Mn |
| Sep 30, 2022 | 110.94 Mn |
| Jun 30, 2022 | 112.91 Mn |
| Mar 31, 2022 | 115.75 Mn |